Encision, Inc.
0.3500+0.12 (+52.2%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · ECIA · USD
Key Stats
Market Cap
5.91MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
8-K
Encision secures $500K funding
Encision Inc. closed a $500,000 private placement on August 19, 2025, issuing 5 million common shares at $0.10 each to accredited investors, including directors, executives, and new shareholders. The funds will support ongoing operations and the early 2026 launch of a new ENT device. This bolsters liquidity while diluting existing shareholders. Yet risks like product acceptance loom large.
10-Q
Q1 FY2026 results
Encision's Q1 FY2026 revenue dipped 1.7% y/y to $1.6M, with product sales down 6% to $1.5M from fewer procedures, yet service revenue surged over 180% to $0.1M via a Vicarious Surgical deal. Gross profit fell 7% to $0.9M, trimming margins to 55% from 58%, while operating expenses eased 2% to $0.9M, yielding a slim operating loss of $20K versus $28K income last year. Net loss hit $41K, widened by $18K higher interest from debt, against prior profit; diluted EPS stayed flat at $(0.00) on 11.9M shares, with no dilution as options proved antidilutive. Cash drained to $48K after $116K operating outflow, but $1.2M working capital and $680K line availability buffer liquidity, alongside $320K line debt, $149K EIDL at 3.75%, and $60K equipment notes at 5-6%. FDA oversight on manufacturing looms as a key risk.
10-K
FY2025 results
Encision's FY25 revenue dipped 0.3% y/y to $6.6M, with product sales down 3% to $6.2M amid fewer non-essential procedures, yet service revenue surged 119% to $338K from Vicarious Surgical engineering work. Gross margins expanded sharply to 54% from 48%, fueled by lower material costs on high-volume items and high-margin services, trimming net loss to $220K from $692K. Q4 momentum showed sequential margin gains, but product trends decelerated without quarterly breakdowns. Liquidity held at $257K cash plus a $396K line draw, with $1M facility available; capex stayed modest at $54K. FY26 outlook eyes revenue growth via AEM expansions and partnerships, though market acceptance lags. Thin trading volatility risks quarterly swings.
10-Q
Q3 FY2025 results
Encision's Q3 FY2025 revenue held steady at $1.6M, flat y/y, while nine-month total dipped 2% y/y to $4.97M amid softer product demand from fewer procedures; service revenue jumped 526% y/y to $0.13M on Vicarious Surgical work. Gross profit climbed 17% y/y to $0.85M in the quarter, lifting margins to 54% from 46% via price hikes and efficiencies, though operating loss narrowed to just $21K from $189K. Cash swelled to $348K, up sharply from $43K at FY start, fueled by $147K operating cash flow and line-of-credit draws; total debt sits at $511K including a $150K EIDL at 3.75% over 30 years, with $718K revolver availability. No non-GAAP metrics disclosed in the 10-Q. Liquidity looks solid for now. Surgeons still pick rivals over AEM gear.
10-Q
Q2 FY2025 results
Encision's Q2 FY2025 revenue dipped 4% y/y to $1.8M, with product sales down 6% to $1.7M from fewer procedures, yet service revenue jumped 37% to $102K under a Vicarious Surgical agreement; gross profit held at 47% margin, matching last year but pressured by $82K inventory reserves. Operating loss widened to $159K from a slim $6K profit, driven by 18% higher sales and marketing on trade shows and commissions, plus 54% R&D ramp-up for product tweaks. Cash swelled to $230K with $193K from operations, line of credit at $79K drawn from $1M facility (no covenants), and $243K secured notes outstanding. Free cash flow hit $150K after $43K capex. FDA oversight demands ongoing compliance scrutiny.
IPO
Website
Employees
Sector
Industry
AORT
Artivion, Inc.
44.99-0.27
ATRC
AtriCure, Inc.
35.44-1.01
CV
CapsoVision, Inc.
4.67-0.01
ENOV
Enovis Corporation
31.99-0.87
ISRG
Intuitive Surgical, Inc.
537.59-7.80
MMSI
Merit Medical Systems, Inc.
81.39-1.40
NOVT
Novanta Inc.
128.61+0.93
POCI
Precision Optics Corporation, I
4.26-0.01
UEEC
United Health Products, Inc.
0.07-0.01
VTAK
Catheter Precision, Inc.
2.44-0.12